Advanced Proteome Therapeutics Corporation
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and i… Read more
Advanced Proteome Therapeutics Corporation (APTCF) - Net Assets
Latest net assets as of April 2023: $-21.74K USD
Based on the latest financial reports, Advanced Proteome Therapeutics Corporation (APTCF) has net assets worth $-21.74K USD as of April 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.75K) and total liabilities ($84.49K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-21.74K |
| % of Total Assets | -34.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 145.09 |
Advanced Proteome Therapeutics Corporation - Net Assets Trend (1997–2022)
This chart illustrates how Advanced Proteome Therapeutics Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Advanced Proteome Therapeutics Corporation (1997–2022)
The table below shows the annual net assets of Advanced Proteome Therapeutics Corporation from 1997 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-07-31 | $-850.89K | +58.68% |
| 2021-07-31 | $-2.06 Million | -48.99% |
| 2020-07-31 | $-1.38 Million | -51.14% |
| 2019-07-31 | $-914.41K | -2.01% |
| 2018-07-31 | $-896.36K | -13.57% |
| 2017-07-31 | $-789.29K | -62.02% |
| 2016-07-31 | $-487.17K | -343.10% |
| 2015-07-31 | $200.40K | +149.36% |
| 2014-07-31 | $-405.97K | +43.90% |
| 2013-07-31 | $-723.68K | -97.18% |
| 2012-07-31 | $-367.02K | -384.39% |
| 2011-07-31 | $129.06K | -62.24% |
| 2010-07-31 | $341.78K | -74.47% |
| 2009-07-31 | $1.34 Million | -44.36% |
| 2008-07-31 | $2.41 Million | +66.83% |
| 2007-07-31 | $1.44 Million | +123887.64% |
| 2006-07-31 | $-1.17K | -101.98% |
| 2005-07-31 | $58.94K | +102.29% |
| 2004-07-31 | $-2.57 Million | -2.61% |
| 2003-07-31 | $-2.50 Million | +69.58% |
| 2002-07-31 | $-8.23 Million | -42.21% |
| 2001-07-31 | $-5.79 Million | -112.63% |
| 2000-07-31 | $-2.72 Million | -309.55% |
| 1999-07-31 | $-664.63K | -113.40% |
| 1998-07-31 | $4.96 Million | +34.09% |
| 1997-07-31 | $3.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Advanced Proteome Therapeutics Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2179777300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (July 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $20.20 Million | 1890.52% |
| Other Comprehensive Income | $2.90 Million | 270.97% |
| Other Components | $279.00K | 26.11% |
| Total Equity | $1.07 Million | 100.00% |
Advanced Proteome Therapeutics Corporation Competitors by Market Cap
The table below lists competitors of Advanced Proteome Therapeutics Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ACL Cables PLC
CM:ACLN0000
|
$7.44K |
|
Northern Star Investment Corp III
PINK:NSTC
|
$7.44K |
|
SKYWORTH DIGITAL (KYW.SG)
STU:KYW
|
$7.44K |
|
WHRL4F
SA:WHRL4F
|
$7.45K |
|
Likewise Group PLC
LSE:LIKE
|
$7.43K |
|
Afastor Corporation
TWO:6707
|
$7.43K |
|
SKYWORTH DIGITAL
MU:KYW
|
$7.42K |
|
Dyna Group International Inc
PINK:DGIX
|
$7.42K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Advanced Proteome Therapeutics Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from -301,907 to 1,068,482, a change of 1,370,389.
- Net income of 759,615 contributed positively to equity growth.
- New share issuances of 150,436 increased equity.
- Other comprehensive income increased equity by 8,201.
- Other factors increased equity by 452,137.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $759.62K | +71.09% |
| Share Issuances | $150.44K | +14.08% |
| Other Comprehensive Income | $8.20K | +0.77% |
| Other Changes | $452.14K | +42.32% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Advanced Proteome Therapeutics Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-07-31 | $2.57 | $0.00 | x |
| 1998-07-31 | $3.25 | $0.00 | x |
| 1999-07-31 | $-0.38 | $0.00 | x |
| 2000-07-31 | $-1.58 | $0.00 | x |
| 2001-07-31 | $-3.31 | $0.00 | x |
| 2002-07-31 | $-4.70 | $0.00 | x |
| 2003-07-31 | $-1.34 | $0.00 | x |
| 2004-07-31 | $-1.28 | $0.00 | x |
| 2005-07-31 | $0.03 | $0.00 | x |
| 2006-07-31 | $0.00 | $0.00 | x |
| 2007-07-31 | $0.17 | $0.00 | x |
| 2008-07-31 | $0.32 | $0.00 | x |
| 2009-07-31 | $0.19 | $0.00 | x |
| 2010-07-31 | $0.05 | $0.00 | x |
| 2011-07-31 | $0.02 | $0.00 | x |
| 2012-07-31 | $0.02 | $0.00 | x |
| 2013-07-31 | $0.00 | $0.00 | x |
| 2014-07-31 | $0.06 | $0.00 | x |
| 2015-07-31 | $0.15 | $0.00 | x |
| 2016-07-31 | $0.10 | $0.00 | x |
| 2017-07-31 | $0.06 | $0.00 | x |
| 2018-07-31 | $0.04 | $0.00 | x |
| 2019-07-31 | $0.04 | $0.00 | x |
| 2020-07-31 | $0.01 | $0.00 | x |
| 2021-07-31 | $-0.01 | $0.00 | x |
| 2022-07-31 | $0.03 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Advanced Proteome Therapeutics Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 71.09%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.60x
- Recent ROE (71.09%) is above the historical average (-64.13%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 64.70% | 24.63% | 1.89x | 1.39x | $2.02 Million |
| 1998 | -34.67% | -35.62% | 0.30x | 3.23x | $-2.22 Million |
| 1999 | 0.00% | -153.44% | 0.32x | 0.00x | $-5.85 Million |
| 2000 | 0.00% | -90.03% | 0.26x | 0.00x | $-1.74 Million |
| 2001 | 0.00% | -103.93% | 0.54x | 0.00x | $-2.49 Million |
| 2002 | 0.00% | -145.50% | 0.84x | 0.00x | $-1.62 Million |
| 2003 | 0.00% | 500.00% | 1.15x | 0.00x | $5.07 Million |
| 2004 | 0.00% | -9.58% | 0.94x | 0.00x | $191.43K |
| 2005 | 4458.62% | 453.66% | 2.95x | 3.33x | $2.62 Million |
| 2006 | 0.00% | -11.07% | 0.00x | 0.00x | $-1.05K |
| 2007 | -209.75% | -3217.38% | 0.04x | 1.79x | $-1.99 Million |
| 2008 | -51.90% | -1201.79% | 0.04x | 1.19x | $-1.35 Million |
| 2009 | -72.76% | -1918.61% | 0.03x | 1.16x | $-1.11 Million |
| 2010 | -335.60% | -13293.93% | 0.02x | 1.61x | $-1.18 Million |
| 2011 | -837.63% | -24850.57% | 0.01x | 3.05x | $-1.09 Million |
| 2012 | -467.73% | 0.00% | 0.00x | 0.92x | $-772.16K |
| 2013 | -3481.31% | 0.00% | 0.00x | 7.58x | $-1.02 Million |
| 2014 | -202.80% | 0.00% | 0.00x | 1.51x | $-1.21 Million |
| 2015 | -53.66% | 0.00% | 0.00x | 0.44x | $-1.05 Million |
| 2016 | -74.75% | 0.00% | 0.00x | 0.10x | $-982.98K |
| 2017 | -99.73% | 0.00% | 0.00x | 0.25x | $-794.40K |
| 2018 | -133.90% | 0.00% | 0.00x | 0.33x | $-800.64K |
| 2019 | -49.98% | 0.00% | 0.00x | 0.25x | $-399.62K |
| 2020 | -155.67% | 0.00% | 0.00x | 0.07x | $-479.58K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.80 Million |
| 2022 | 71.09% | 0.00% | 0.00x | 0.60x | $652.77K |
Industry Comparison
This section compares Advanced Proteome Therapeutics Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Advanced Proteome Therapeutics Corporation (APTCF) | $-21.74K | 64.70% | N/A | $7.43K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |